Administratiekantoor Westend Stichting
CIK 1460840 · last filed 2026-06-17
Administratiekantoor Westend Stichting is a corporate insider who has filed 10 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing shows the insider sold $270.9M of CAVA on Jun 17, 2026. Across all open-market trades the lifetime net is −$997.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.30B across reported positions. 74 SEC filings were submitted jointly with Westend S.A.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BUFF price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
AMSTERDAM 1096 AS
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAVA | Director | 6,507,990 | $61.20 | $398.26M | -$458.50M | 2 | 2026-06-17 |
| LXRX | Director | 35,402,689 | $1.84 | $65.14M | $7.89M | 3 | 2024-05-14 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 82,891 | $15.70 | $1.30M | $712.3K | 1 | 2023-02-23 |
| SQZ Biotechnologies Co (SQZ) Delisted | 10%+ Owner | 1,141,308 | $0.43 | $496.5K | $7.44M | 1 | 2020-11-03 |
| BUFF | Director | 114,987,547 | $53.78 | $6.18B | -$569.29M | 1 | 2015-07-27 |
| WTW | 10%+ Owner | 11,082,874 | $329.14 | $3.65B | $2.92M | 1 | 2014-08-14 |
| Ceres, Inc. (CERE) Delisted | 10%+ Owner | 507,117 | $44.96 | $22.80M | $11.00M | 1 | 2012-02-28 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | CAVA | Sell (S) | −3,000,000 | -$270.90M | EDGAR |
| 2024-05-14 | LXRX | Mixed | +57,546,100 | $0 | EDGAR |
| 2024-02-29 | CAVA | Sell (S) | −3,500,000 | -$187.60M | EDGAR |
| 2023-02-23 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +400,000 | $712.3K | EDGAR |
| 2022-08-09 | LXRX | Buy (P) | +2,426,070 | $6.07M | EDGAR |
| 2020-11-03 | SQZ Biotechnologies Co (SQZ) Delisted | Mixed | +1,606,308 | $7.44M | EDGAR |
| 2017-11-17 | LXRX | Buy (P) | +180,727 | $1.83M | EDGAR |
| 2015-07-27 | BUFF | Sell (S) | −28,464,603 | -$569.29M | EDGAR |
| 2014-08-14 | WTW | Buy (P) | +126,620 | $2.92M | EDGAR |
| 2012-02-28 | Ceres, Inc. (CERE) Delisted | Mixed | +4,056,935 | $11.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.